Tertiary prophylaxis in adults: is there a rationale?
Identifieur interne : 005592 ( Main/Exploration ); précédent : 005591; suivant : 005593Tertiary prophylaxis in adults: is there a rationale?
Auteurs : A. Gringeri [Italie] ; T. Lambert [France] ; A. Street [Australie] ; L. Aledort [États-Unis]Source :
- Haemophilia [ 1351-8216 ] ; 2012-09.
Descripteurs français
- Wicri :
- topic : Participation sociale.
English descriptors
- KwdEn :
- Adult patients, Arthropathy, Better quality, Blackwell publishing, Bleeds, Centre, Clinical outcomes, Coagulation, Coagulation factor, Cohort, Cost effectiveness, Factor viii, Full paper, Haemophilia, Haemophilia care, Haemost, Hemophilia, Higher costs, Higher factor consumption, Joint bleeds, Orthopaedic, Orthopaedic scores, Primary prophylaxis, Prophylactic, Prophylactic treatment, Prophylaxis, Prophylaxis program, Regimen, Regular prophylaxis, Secondary prophylaxis, Severe arthropathy, Severe haemophilia, Severe hemophilia, Social participation, Suppl, Tagliaferri, Tertiary, Tertiary prophylaxis, Thromb, Thromb haemost, Viii.
- Teeft :
- Adult patients, Arthropathy, Better quality, Blackwell publishing, Bleeds, Centre, Clinical outcomes, Coagulation, Coagulation factor, Cohort, Cost effectiveness, Factor viii, Full paper, Haemophilia, Haemophilia care, Haemost, Hemophilia, Higher costs, Higher factor consumption, Joint bleeds, Orthopaedic, Orthopaedic scores, Primary prophylaxis, Prophylactic, Prophylactic treatment, Prophylaxis, Prophylaxis program, Regimen, Regular prophylaxis, Secondary prophylaxis, Severe arthropathy, Severe haemophilia, Severe hemophilia, Social participation, Suppl, Tagliaferri, Tertiary, Tertiary prophylaxis, Thromb, Thromb haemost, Viii.
Abstract
There is lack of evidence‐based recommendations or clear‐cut consensus regarding the clinical and economic utility of regular prophylaxis started in adulthood, with the aim of keeping the clinical situation from getting worse by prevention of further bleeds contributing to increasing musculo‐skeletal or other morbidity in haemophilia. Such a prophylaxis program has been shown in relatively small cohorts to be effective in reducing bleeding occurrence, with a variable effect on the joint status, but with significantly higher factor consumption and consequently higher costs than on‐demand therapy. There has been no attempt to identify subsets of patients who may benefit from “tertiary” prophylaxis more than others, for example, due to their bleeding phenotype and/or requirements for product issued on‐demand or to identify the dosage that provides the optimal balance of clinical benefit and cost effectiveness. This article reviews the published literature on prophylaxis started beyond the age of 18 years, the barriers to the uptake of prophylaxis programs particularly in adults and highlights areas in need of further research.
Url:
DOI: 10.1111/j.1365-2516.2012.02843.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002924
- to stream Istex, to step Curation: 002924
- to stream Istex, to step Checkpoint: 000517
- to stream Main, to step Merge: 005859
- to stream Main, to step Curation: 005592
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tertiary prophylaxis in adults: is there a rationale?</title>
<author><name sortKey="Gringeri, A" sort="Gringeri, A" uniqKey="Gringeri A" first="A." last="Gringeri">A. Gringeri</name>
</author>
<author><name sortKey="Lambert, T" sort="Lambert, T" uniqKey="Lambert T" first="T." last="Lambert">T. Lambert</name>
</author>
<author><name sortKey="Street, A" sort="Street, A" uniqKey="Street A" first="A." last="Street">A. Street</name>
</author>
<author><name sortKey="Aledort, L" sort="Aledort, L" uniqKey="Aledort L" first="L." last="Aledort">L. Aledort</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:DCCF75B35BA2C60CE99BE2DCA109489F82262339</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1111/j.1365-2516.2012.02843.x</idno>
<idno type="url">https://api.istex.fr/document/DCCF75B35BA2C60CE99BE2DCA109489F82262339/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002924</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002924</idno>
<idno type="wicri:Area/Istex/Curation">002924</idno>
<idno type="wicri:Area/Istex/Checkpoint">000517</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000517</idno>
<idno type="wicri:doubleKey">1351-8216:2012:Gringeri A:tertiary:prophylaxis:in</idno>
<idno type="wicri:Area/Main/Merge">005859</idno>
<idno type="wicri:Area/Main/Curation">005592</idno>
<idno type="wicri:Area/Main/Exploration">005592</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Tertiary prophylaxis in adults: is there a rationale?</title>
<author><name sortKey="Gringeri, A" sort="Gringeri, A" uniqKey="Gringeri A" first="A." last="Gringeri">A. Gringeri</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine, University of Milan, and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Lambert, T" sort="Lambert, T" uniqKey="Lambert T" first="T." last="Lambert">T. Lambert</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Traitement des Hémophiles, Hôpital de Bicêtre AP‐HP, Le Kremlin Bicêtre</wicri:regionArea>
<wicri:noRegion>Le Kremlin Bicêtre</wicri:noRegion>
<wicri:noRegion>Le Kremlin Bicêtre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Street, A" sort="Street, A" uniqKey="Street A" first="A." last="Street">A. Street</name>
<affiliation wicri:level="3"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Ronald Sawers Haemophilia Centre, Alfred Health, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aledort, L" sort="Aledort, L" uniqKey="Aledort L" first="L." last="Aledort">L. Aledort</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, NY, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Haemophilia</title>
<title level="j" type="alt">HAEMOPHILIA</title>
<idno type="ISSN">1351-8216</idno>
<idno type="eISSN">1365-2516</idno>
<imprint><biblScope unit="vol">18</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="722">722</biblScope>
<biblScope unit="page" to="728">728</biblScope>
<biblScope unit="page-count">7</biblScope>
<date type="published" when="2012-09">2012-09</date>
</imprint>
<idno type="ISSN">1351-8216</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-8216</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult patients</term>
<term>Arthropathy</term>
<term>Better quality</term>
<term>Blackwell publishing</term>
<term>Bleeds</term>
<term>Centre</term>
<term>Clinical outcomes</term>
<term>Coagulation</term>
<term>Coagulation factor</term>
<term>Cohort</term>
<term>Cost effectiveness</term>
<term>Factor viii</term>
<term>Full paper</term>
<term>Haemophilia</term>
<term>Haemophilia care</term>
<term>Haemost</term>
<term>Hemophilia</term>
<term>Higher costs</term>
<term>Higher factor consumption</term>
<term>Joint bleeds</term>
<term>Orthopaedic</term>
<term>Orthopaedic scores</term>
<term>Primary prophylaxis</term>
<term>Prophylactic</term>
<term>Prophylactic treatment</term>
<term>Prophylaxis</term>
<term>Prophylaxis program</term>
<term>Regimen</term>
<term>Regular prophylaxis</term>
<term>Secondary prophylaxis</term>
<term>Severe arthropathy</term>
<term>Severe haemophilia</term>
<term>Severe hemophilia</term>
<term>Social participation</term>
<term>Suppl</term>
<term>Tagliaferri</term>
<term>Tertiary</term>
<term>Tertiary prophylaxis</term>
<term>Thromb</term>
<term>Thromb haemost</term>
<term>Viii</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adult patients</term>
<term>Arthropathy</term>
<term>Better quality</term>
<term>Blackwell publishing</term>
<term>Bleeds</term>
<term>Centre</term>
<term>Clinical outcomes</term>
<term>Coagulation</term>
<term>Coagulation factor</term>
<term>Cohort</term>
<term>Cost effectiveness</term>
<term>Factor viii</term>
<term>Full paper</term>
<term>Haemophilia</term>
<term>Haemophilia care</term>
<term>Haemost</term>
<term>Hemophilia</term>
<term>Higher costs</term>
<term>Higher factor consumption</term>
<term>Joint bleeds</term>
<term>Orthopaedic</term>
<term>Orthopaedic scores</term>
<term>Primary prophylaxis</term>
<term>Prophylactic</term>
<term>Prophylactic treatment</term>
<term>Prophylaxis</term>
<term>Prophylaxis program</term>
<term>Regimen</term>
<term>Regular prophylaxis</term>
<term>Secondary prophylaxis</term>
<term>Severe arthropathy</term>
<term>Severe haemophilia</term>
<term>Severe hemophilia</term>
<term>Social participation</term>
<term>Suppl</term>
<term>Tagliaferri</term>
<term>Tertiary</term>
<term>Tertiary prophylaxis</term>
<term>Thromb</term>
<term>Thromb haemost</term>
<term>Viii</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Participation sociale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">There is lack of evidence‐based recommendations or clear‐cut consensus regarding the clinical and economic utility of regular prophylaxis started in adulthood, with the aim of keeping the clinical situation from getting worse by prevention of further bleeds contributing to increasing musculo‐skeletal or other morbidity in haemophilia. Such a prophylaxis program has been shown in relatively small cohorts to be effective in reducing bleeding occurrence, with a variable effect on the joint status, but with significantly higher factor consumption and consequently higher costs than on‐demand therapy. There has been no attempt to identify subsets of patients who may benefit from “tertiary” prophylaxis more than others, for example, due to their bleeding phenotype and/or requirements for product issued on‐demand or to identify the dosage that provides the optimal balance of clinical benefit and cost effectiveness. This article reviews the published literature on prophylaxis started beyond the age of 18 years, the barriers to the uptake of prophylaxis programs particularly in adults and highlights areas in need of further research.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Lombardie</li>
<li>Victoria (État)</li>
<li>État de New York</li>
</region>
<settlement><li>Melbourne</li>
<li>Milan</li>
</settlement>
</list>
<tree><country name="Italie"><region name="Lombardie"><name sortKey="Gringeri, A" sort="Gringeri, A" uniqKey="Gringeri A" first="A." last="Gringeri">A. Gringeri</name>
</region>
<name sortKey="Gringeri, A" sort="Gringeri, A" uniqKey="Gringeri A" first="A." last="Gringeri">A. Gringeri</name>
</country>
<country name="France"><noRegion><name sortKey="Lambert, T" sort="Lambert, T" uniqKey="Lambert T" first="T." last="Lambert">T. Lambert</name>
</noRegion>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Street, A" sort="Street, A" uniqKey="Street A" first="A." last="Street">A. Street</name>
</region>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Aledort, L" sort="Aledort, L" uniqKey="Aledort L" first="L." last="Aledort">L. Aledort</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005592 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005592 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:DCCF75B35BA2C60CE99BE2DCA109489F82262339 |texte= Tertiary prophylaxis in adults: is there a rationale? }}
This area was generated with Dilib version V0.6.33. |